Abstract
Background: The pandemic of severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is a multi-system disease caused by a diffuse systemic process involving a complex interaction of the inflammatory, immunological and coagulative cascades. This study aims to identify the most effective biomarkers to predict a poor outcome in the intensive care unit patients with severe COVID-19 disease.
Methods: A single-centre retrospective observational study enrolled 69 deceased and 20 recovered patients treated in the Intensive Care Unit of the General Hospital Gradiska in the period from March 1, 2021. until April 1, 2022. We evaluated the leukocytes, lymphocytes, neutrophils, platelets, hemoglobin, neutrophil lymphocyte ratio (NPR), platelet lymphocyte ratio (PLR), systemic immune-inflammation index (SII). In addition, we evaluated the IL-6, ferritin, CRP, D-dimer, magnesium, bilirubin and lactate dehydrogenase.
Results: Between deceased and recovered patients on admission to the ICU, there was a significant difference between the following parameters: leukocytes x109/L 11.5 (8.86-14.75) vs 9.4 (5.9-11.9), p =0.026; neutrophils x109/L 10.15 (7.81-12.74) vs 8.60 (4.8-10.3) p=0.022; NLR 15.01 (10.60-24.33) vs 9.45 (5.10-14.90) p=0.02; SII 3712 (2240-6543) vs 1949 (993-3720) p=0.003. The magnesium level increased significantly over time in the group of patients who died, while the hemoglobin level and platelet count decreased. ROC analysis showed the following AUC values: leukocytes 0.774; neutrophils 0.781; NLR 0.786; SII 0.776; D-dimer 0.741and bilrubine 0.713.
Conclusions: In this retrospective study leukocytes, neutrophils, NLR, SII, D-dimer, bilirubin determined at hospital admission had a high value in predicting death among patients with severe COVID-19.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.